文献速递甲状腺核医学核素与放射性配体治疗

晚期进展性甲状腺髓样癌患者的肽受体放射性核素治疗:疗效、安全性和生存预测因素

Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
PubMed 文献 · Clin Nucl Med · 2023-01-12

本研究评估了28例晚期进展性生长抑素受体阳性甲状腺髓样癌患者接受177Lu或90Y标记生长抑素类似物肽受体放射性核素治疗的安全性和疗效。结果显示治疗耐受良好,疾病控制率56%,中位总生存63.7个月,中位无进展生存10.1个月。骨转移是总生存的独立不良预后因素。

要点

  • 肽受体放射性核素治疗在晚期进展性甲状腺髓样癌中耐受良好且有效。
  • 骨转移患者总生存和无进展生存均较无骨转移者差,骨转移是总生存的独立不良预后因素。
  • 按RECIST标准疾病控制率为56%,按分子影像标准疾病控制率为72%。

核心结论

  • 肽受体放射性核素治疗在晚期、侵袭性甲状腺髓样癌患者中耐受良好且有效。
  • 骨转移是总生存的独立不良预后因素。

研究设计与样本

  • 2003年9月至2019年6月在德国Zentralklinik Bad Berka纳入28例进展性、生长抑素受体阳性的晚期甲状腺髓样癌患者(15男13女,平均年龄49±14岁),接受177Lu或90Y标记生长抑素类似物的肽受体放射性核素治疗。
  • 毒性按不良事件通用术语标准5.0版分级,疗效按RECIST 1.1及欧洲癌症研究与治疗组织分子影像标准评估,采用Kaplan-Meier法计算无进展生存和总生存,并用单因素和多因素Cox回归分析生存相关因素。

主要发现

  • 共实施77个肽受体放射性核素治疗周期,平均累积给药活度为16.0±7.8 GBq。
  • 随访3至140个月,除1例(4%)发生3级贫血(可能与疾病进展相关)外,未记录到急性或长期3/4级毒性。
  • 按RECIST标准,治疗3至4个月后疾病控制率为56%(部分缓解12%,疾病稳定44%);按分子疗效评估疾病控制率更高,为72%。
  • 中位总生存和无进展生存分别为63.7个月和10.1个月;1年、3年、5年和10年总生存率分别为84%、65%、57%和18%;1年、2年和5年无进展生存率分别为42%、21%和13%。
  • 骨转移患者较无骨转移患者总生存更差(中位总生存58.7 vs 92.3个月,P=0.035,风险比2.7,95%置信区间0.92-7.84);无进展生存两组差异未达统计学显著(中位无进展生存8.5 vs 12.8个月,P=0.592,风险比1.2,95%置信区间0.56-2.76)。

关键数值与推荐

  • 毒性分级采用不良事件通用术语标准5.0版。
  • 疗效评估采用RECIST 1.1标准及欧洲癌症研究与治疗组织分子影像标准。
  • 生存分析采用Kaplan-Meier法,预后因素分析采用单因素和多因素Cox回归。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Progressive metastatic medullary thyroid carcinoma (MTC) is often characterized by rapid disease progression and poor prognosis, with only few therapeutic options available. Peptide receptor radionuclide therapy (PRRT) has demonstrated remarkable success in the management of gastroenteropancreatic neuroendocrine tumors and has also been suggested to treat MTC. However, evidence on its effectiveness and long-term outcome for this indication is still limited. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC and to determine survival. Potential predictors of survival were also evaluated. METHODS: From September 2003 to June 2019, 28 patients (15 men and 13 women; mean age, 49 ± 14 years) with progressive, somatostatin receptor-positive advanced MTC received PRRT with 177Lu- or 90Y-labeled somatostatin analogs at Zentralklinik Bad Berka, Germany. Toxicity was graded according to Common Terminology Criteria for Adverse Events version 5.0. Treatment response was evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors) 1.1, as well as molecular imaging criteria (European Organisation for Research and Treatment of Cancer). Kaplan-Meier analysis was used to calculate progression-free survival (PFS) and overall survival (OS), defined from the start of PRRT. Univariate and multivariate Cox regression analyses were performed to identify parameters associated with PFS and OS. RESULTS: Seventy-seven cycles of PRRT were administered (mean cumulative administered activity, 16.0 ± 7.8 GBq). No acute or long-term grade 3/4 toxicity was recorded with a follow-up of 3 to 140 months, except for 1 patient (4%) who suffered from grade 3 anemia (possibly related to disease progression). According to the RECIST criteria, the disease control rate after 3 to 4 months of PRRT was 56% (partial remission, 12%; stable disease, 44%). The disease control rate (72%) was higher by molecular response evaluation. Median OS and PFS were 63.7 and 10.1 months, respectively. The annual OS rates were 84% at 1 year, 65% at 3 years, 57% at 5 years, and 18% at 10 years. The annual PFS rates were 42% at 1 year, 21% at 2 years, and 13% at 5 years. Patients with bone metastases had poorer OS and PFS than those without metastases (median OS, 58.7 vs 92.3 months [P = 0.035; hazard ratio, 2.7; 95% confidence interval, 0.92-7.84]; median PFS, 8.5 vs 12.8 months [P = 0.592; hazard ratio, 1.2; 95% confidence interval, 0.56-2.76]). CONCLUSIONS: Peptide receptor radionuclide therapy was well tolerated and effective in patients with advanced, aggressive MTC. Bone metastasis was an independent adverse prognostic factor for OS.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu Q, Kulkarni HR, Zhao T, et al. Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors. Clin Nucl Med. 2023. PMID: 36723881. doi:10.1097/RLU.0000000000004539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。